Clinical Trials
69 trialsPhase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Memorial Sloan Kettering Cancer Center
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
National Cancer Institute (NCI)
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
Alliance for Clinical Trials in Oncology
DOSa
M.D. Anderson Cancer Center
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
M.D. Anderson Cancer Center
TRABEPIO
Mario Negri Institute for Pharmacological Research
PROSARC-1
Oslo University Hospital
PROSARC-2
Oslo University Hospital
TAIS
Fudan University
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
Memorial Sloan Kettering Cancer Center
CDK4i
Pfizer
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
PERELI
Lund University Hospital
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
HRYZ Biotech Co.
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Shanghai Pharma Biotherapeutics USA Inc.
Study of Abemaciclib in Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
APX005M and Doxorubicin in Advanced Sarcoma
Columbia University
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
Alliance for Clinical Trials in Oncology
TTI-621-03
Pfizer
First-line Treatment of Advanced/unresectable DDLPS
Fudan University
Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Columbia University
ATX-101
Columbia University
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Sarcoma Alliance for Research through Collaboration
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
Canadian Cancer Trials Group
Rosiglitazone in Treating Patients With Liposarcoma
Dana-Farber Cancer Institute
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Northwestern University
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
TRAVELL
Italian Sarcoma Group
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Ph II Cabazitaxel DD Liposarcoma
European Organisation for Research and Treatment of Cancer - EORTC
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
SINDIR
Maria Sklodowska-Curie National Research Institute of Oncology
APLIPO
Institut Bergonié
UN-RESARC
Maria Sklodowska-Curie National Research Institute of Oncology
Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Grupo Espanol de Investigacion en Sarcomas
IMDZ-C232
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
National Cancer Institute (NCI)
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Memorial Sloan Kettering Cancer Center
A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
Assaf-Harofeh Medical Center
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
National Cancer Institute (NCI)
Bevacizumab and Radiation Therapy for Sarcomas
Massachusetts General Hospital
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Vector Oncology